Palvella Therapeutics, Inc.
PVLA
Updated: 23/09/2026, 12:08:21
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
No summaries found.
- Share price
- $158.13
- Market cap
- $2.27B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Wesley H. Kaupinen
- Employees
- 29
- IPO date
- 02/01/2015
- Beta
- -0.16508117
- Last dividend
- $0.00
- Day range
- $153.64 – $160.84
- 52-week range
- $56.55 – $161.38
- 1-day performance
- 3.08%
- 1-year performance
- 179.65%
- Current drawdown (1Y)
- -2.01%
- CIK
- 0001583648
- CUSIP
- 697947109
- ISIN
- US6979471090
- Created
- 07/12/2025, 13:51:22
- Last update
- 23/09/2026, 12:08:21
Track Palvella Therapeutics, Inc. with an AI analyst
See which prediction-market events move PVLA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Palvella Therapeutics: Qtorin Continues Making Progress, So I Remain Bullish
Seeking Alpha • STOCK • 05/06/2026, 09:30:00
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
GlobeNewsWire • STOCK • 03/06/2026, 09:30:00
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
GlobeNewsWire • STOCK • 20/05/2026, 18:30:00
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
GlobeNewsWire • STOCK • 15/05/2026, 09:30:00
Palvella Therapeutics Q1 Earnings Call Highlights
MarketBeat • STOCK • 08/05/2026, 20:14:55
Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 08/05/2026, 02:31:14
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
GlobeNewsWire • STOCK • 20/04/2026, 09:30:00
Palvella Therapeutics Appoints John D. Doux, M.D.
GlobeNewsWire • STOCK • 13/04/2026, 09:30:00
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
GlobeNewsWire • STOCK • 31/03/2026, 09:30:00
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
GlobeNewsWire • STOCK • 30/03/2026, 09:30:00
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
GlobeNewsWire • STOCK • 27/03/2026, 11:30:00
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
GlobeNewsWire • STOCK • 24/03/2026, 08:30:00